Amgen stock rebounded Wednesday, shaking off "overdone" fears that its monthly weight-loss shot, MariTide, causes excessive bone mineral density loss. Please watch the video at Investors.com - How ...
Shares of Amgen and 3M are trading lower Tuesday afternoon, sending the Dow Jones Industrial Average into negative territory. Shares of Amgen and 3M are contributing to the blue-chip gauge's intraday ...
The Amgen Irish Open has been confirmed in a September date at The K Club as part of the DP World Tour’s 2025 schedule.
Tezspire is currently approved for the treatment of severe asthma in the US, EU, Japan, and nearly 60 countries across the globe. It is approved as a single-use pre-filled syringe and auto-injector ...
TEZSPIRE demonstrated a statistically significant and clinically meaningful reduction in nasal polyp size and reduced nasal congestion compared to placebo ...
(IN BRIEF) A Phase III trial of Tezspire (tezepelumab) by AstraZeneca and Amgen has shown significant benefits for patients ...
Vaccinex has global commercial and development rights to pepinemab and is the sponsor of the KEYNOTE-B84 study which is being performed in collaboration with Merck Sharp & Dohme Corp, a subsidiary of ...
In May 2024, Novartis announced new data that confirm the long-term efficacy and safety of remibrutinib, a highly selective ...
Background Pulmonary microvasculature alterations are implicated in emphysema pathogenesis, but the association between ...
Regeneron might be ready for competition with its blockbuster drug Eylea, but it's not clear that investors are. On Thursday ...
While Amgen didn’t reveal much about upcoming readouts for its highly-anticipated weight loss drugs during third-quarter earnings, the company did detail cer ...
Discover five T cell engager companies that have emerged in recent times, as this class of therapeutics is set to take off.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback